Signature Resources Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Signature Resources Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$139	Sell	38 -501	-93%	-$1.67K	﹤0.01%	684
2026 Q1	$1.66K	Buy	539 +501	+1,318%	+$1.94K	﹤0.01%	547
2025 Q4	$155	Hold	38	–	–	﹤0.01%	677
2025 Q3	$185	Hold	38	–	–	﹤0.01%	507
2025 Q2	$192	Hold	38	–	–	﹤0.01%	525
2025 Q1	$201	Hold	38	–	–	﹤0.01%	371
2024 Q4	$257	Buy	+38	New	+$255	﹤0.01%	360

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

TMC

Themes Management Co Greenwich, Connecticut $151M AUM

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

Signature Resources Capital Management's RXRX Position: Q2 2026 in Review

Signature Resources Capital Management reduced its Recursion Pharmaceuticals (RXRX) stake by 93% in Q2 2026, selling an estimated $1.67K and leaving 38 shares worth $139. The position accounts for ﹤0.01% of the portfolio, ranked #684.

Signature Resources Capital Management first reported a position in RXRX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.66K in Q1 2026. 58 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Signature Resources Capital Management held 38 shares of Recursion Pharmaceuticals worth $139 as of Q2 2026.
Signature Resources Capital Management sold 501 Recursion Pharmaceuticals shares in Q2 2026, an estimated $1.67K.
Recursion Pharmaceuticals made up ﹤0.01% of Signature Resources Capital Management's portfolio in Q2 2026, its #684 holding.
Signature Resources Capital Management first reported a position in Recursion Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
Signature Resources Capital Management's Recursion Pharmaceuticals position peaked at $1.66K in Q1 2026.
58 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Signature Resources Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.